Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|January 13, 2025

Managed Care Partnerships and Continuity of Care

A panelist discusses how strategic managed care partnerships can streamline care transitions between treatment settings to ensure uninterrupted support and monitoring for patients with Lambert-Eaton myasthenic syndrome.

Episodes in this series

EP. 1 LEMS and SCLC: Unraveling the Neuromuscular-Cancer Connection

EP. 1 LEMS and SCLC: Unraveling the Neuromuscular-Cancer Connection

EP. 2 Strategies to Alleviate the Clinical and Economic Burden of LEMS

EP. 2 Strategies to Alleviate the Clinical and Economic Burden of LEMS

EP. 3 The Clinical and Economic Impact of LEMS in SCLC Care

EP. 3 The Clinical and Economic Impact of LEMS in SCLC Care

1 expert is featured in this series.

EP. 4 Using Technology for Early Detection of LEMS

1 expert is featured in this series.

EP. 5 Team- and System-Based Approaches to Managing LEMS and Ensuring Access

1 expert is featured in this series.

EP. 6 The Role of Patient Engagement Tools and Patient Advocacy Groups in LEMS Care

1 expert is featured in this series.

EP. 7 Managed Care Partnerships and Continuity of Care

Video content above is prompted by the following:

How can managed care partnerships enhance continuity of care for patients transitioning between different treatment settings?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Man coughing. | Image credit: @sebra_AdobeStock.jpeg

CHMP Backs Nerandomilast for IPF and PPF in EU

BySabrina McCrear

June 10th 2026

From Patient Selection to Future Therapies: JAK Inhibitors in Alopecia Areata

ByArash Mostaghimi, MD, MPH, FAAD

June 10th 2026

Deuruxolitinib in Alopecia Areata: Trial Data, Onset of Action, and Adverse Event Management

ByArash Mostaghimi, MD, MPH, FAAD

June 10th 2026

Comparing the Clinical Trials of Baricitinib and Ritlecitinib in Alopecia Areata

ByArash Mostaghimi, MD, MPH, FAAD

June 10th 2026

JAK Inhibitors in Alopecia Areata: Clinical Rationale and FDA-Approved Therapies

ByArash Mostaghimi, MD, MPH, FAAD

June 10th 2026

Trending on AJMC

GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale

ACA Enrollment Erosion Deepens After Open Enrollment Ends

Efgartigimod Effective in Broad Subsets of Patients With gMG

Shields Health Solutions Partners With Baptist Health on Specialty Pharmacy

Alopecia Areata Takes a Hidden Toll on Work, Relationships, and Self-Care